Plaintiff

Coalition for Affordable Drugs VI LLC

1 case as plaintiff.

Cases
1
Active
0
1 closed
Filed
2015
Top venue
PTAB
1 case

Company profile

Coalition for Affordable Drugs VI LLC (also styled "CFAD VI" or "Affordable Drugs VI, LLC") is one of a series of shell entities created in 2015 under the "Coalition for Affordable Drugs" (CFAD) banner. It has no headquarters or operations of its own; filings with the USPTO state it is a wholly owned subsidiary of Hayman Credes Master Fund, L.P., part of the Dallas-based Hayman Capital Management complex founded by hedge-fund manager J. Kyle Bass. Named real parties in interest include Bass, Hayman entities, and patent consultant Erich Spangenberg and his firm IP Navigation Group (IPNav). No employee count, revenue, or public ticker applies — it is a private, single-purpose vehicle.

Products / operations. CFAD VI sells nothing and practices no patents. It exists to file inter partes review (IPR) petitions at the Patent Trial and Appeal Board challenging pharmaceutical patents, while affiliated Hayman funds took short positions in the target companies and long positions in would-be beneficiaries. It is best characterized not as a patent-asserting NPE but as a "reverse" petitioner — an NPE-style entity that attacks others' patents for financial return rather than asserting an acquired portfolio.

Litigation posture. The structured data show 1 tracked case, all as plaintiff (PTAB petitioner) and 0 as defendant, consistent with a one-purpose challenger. No district court suits are recorded; activity clusters entirely at the PTAB, not in plaintiff-friendly district venues.

Notable case. Coalition for Affordable Drugs VI LLC v. Celgene Corp. (filed May 2015) covered Celgene's U.S. 6,315,720 and related patents on restricted distribution of thalidomide/lenalidomide. Celgene moved for sanctions, arguing the IPRs were an abuse of process tied to short selling; the PTAB denied sanctions on September 25, 2015 (IPR2015-01092, -01096, -01102, -01103, -01169), holding an economic motive is not by itself abuse. Final written decisions in 2017 invalidated most claims, though PTAB rehearing upheld claim 10. Reporting indicates the CFAD campaign largely wound down afterward, with the overseeing fund closed.

Keep this research.

Save to your free workspace, then choose whether to receive updates.